<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">Routine blood examination should be continue in the management of lung cancer patients during antitumor treatment to monitor the extent of myelosuppression through the important concerns including platelets, leukocyte counts, neutrophils, and red blood cells and hemoglobin levels. Mild to moderate myelosuppression can be treated with corresponding oral drugs. However, there are some conditions need to be treated under professional doctor guidance: neutrophil count &lt; 1.0 × 10
 <sup>9</sup>/L, leukocyte count &lt; 2.0 × 10
 <sup>9</sup>/L, platelet count &lt; 50 × 10
 <sup>9</sup>/L, hemoglobin level &lt; 100 g/L, or infection symptoms, or the occurrence of gum/nose bleeds and skin congestion.
</p>
